Literature DB >> 22469102

Quality of life and metabolic disorders in patients with obstructive sleep apnea.

Emel Bulcun1, Aydanur Ekici, Mehmet Ekici.   

Abstract

PURPOSE: Quality of life (QoL) may be poor in patients with sleep apnea depending on multifactorial reasons. In this observational study, we examined the factors determining QoL in patients with obstructive sleep apnea (OSA) and nonapneic snoring subjects.
METHODS: Complete assessments were obtained on 111 subjects who diagnosed OSA and 18 nonapneic snoring subjects. Fasting blood samples of all of subjects were taken to determine insulin resistance (IR) and oral glucose tolerance tests were performed to diagnose disorders of glucose metabolism (DGM). Quality of life, with short form (SF)-36, and excessive daytime sleepiness, with epwort sleepness scale (ESS), were evaluated.
RESULTS: The mean age of the patients with OSA was higher than that of the nonapneic snoring subjects (48.4 ± 9.6 years and 43.0 ± 11.8 years, respectively; p=0.03). BMI was also significantly higher in the patients with OSA than in the nonapneic snorers (31.0 ± 4.5 and 27.1 ± 4.0, respectively; p=0.001). The mental health component in the patients with OSA was slightly but not significantly lower than the nonapneic snoring subjects (p=0.05). A negative correlation among most domains of quality of life with scores of ESS, body mass index (BMI), presence of hypertension (HT) and DGM was found. Only physicial functioning was negatively correlated with apnea hypopnea index (AHI). In linear regression analysis, there were negative associations among physical functioning with BMI, presence of HT and DGM while there was no association between physicial functioning and AHI. In addition, there were negative correlations between mental health component with BMI and presence of HT in the multivariate analysis. Obese patients with OSA had lower physicial and mental components compared with nonobese patients with OSA.
CONCLUSION: The impact of OSA on quality of life can be attributed to excessive daytime sleepiness. Obesity and metabolic disorders in patients with OSA may also negatively affect the quality of life.

Entities:  

Mesh:

Year:  2012        PMID: 22469102     DOI: 10.25011/cim.v35i2.16294

Source DB:  PubMed          Journal:  Clin Invest Med        ISSN: 0147-958X            Impact factor:   0.825


  6 in total

1.  Sleep quality in women who use different contraceptive methods.

Authors:  Helena Hachul; Aline Rodrigues Bisse; Zila M Sanchez; Fábio Araujo; Cristina A F Guazzelli; Sergio Tufik; Márcia Barbieri
Journal:  Sleep Sci       Date:  2020 Apr-Jun

2.  Thalamic altered spontaneous activity and connectivity in obstructive sleep apnea syndrome.

Authors:  Emiliano Santarnecchi; Giulia Sprugnoli; Isabella Sicilia; Juergen Dukart; Francesco Neri; Sara M Romanella; Alfonso Cerase; Giampaolo Vatti; Raffaele Rocchi; Alessandro Rossi
Journal:  J Neuroimaging       Date:  2021-12-28       Impact factor: 2.324

3.  Impaired sustained attention and lapses are present in patients with mild obstructive sleep apnea.

Authors:  Gabriela Pontes Luz; Thais Moura Guimarães; Terri E Weaver; Luiz E Nery; Luciana Oliveira E Silva; Luciana Badke; Glaury Coelho; Aline Millani-Carneiro; Sergio Tufik; Lia Bittencourt
Journal:  Sleep Breath       Date:  2015-11-12       Impact factor: 2.816

Review 4.  Obesity Disease and Surgery.

Authors:  Abdulrahman Saleh Al-Mulhim; Hessah Abdulaziz Al-Hussaini; Bashaeer Abdullah Al-Jalal; Rehab Omar Al-Moagal; Sara Abdullah Al-Najjar
Journal:  Int J Chronic Dis       Date:  2014-04-28

5.  Swallowing outcome to speech therapy intervention in resistant hypertensive patients with obstructive sleep apnea.

Authors:  Thalyta Georgia Vieira Borges; Carla Rocha Muniz; Flavia Rodrigues Ferreira; Mariana Pinheiro Brendim; Elizabeth Silaid Muxfeldt
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-09-13       Impact factor: 3.236

6.  Health status in subjects with suspected obstructive sleep apnea and comparison with a general population.

Authors:  Kornelia K Beiske; Knut Stavem
Journal:  Sci Rep       Date:  2018-04-03       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.